Daxor Corp Finalizes $8.14M Direct Stock Offering at $11.75/Share, Resulting in Significant Dilution

summarizeSummary

This 8-K formalizes the terms and closing of a significant direct offering, following earlier prospectus filings, including the 424B4 on January 26, 2026, which announced the finalization of the offering. The company raised approximately $8.14 million in net proceeds by selling 765,958 shares at $11.75 per share. While the offering price was at a modest discount to the current market price, the capital raise is substantial relative to Daxor's market capitalization, indicating significant dilution for existing shareholders. The proceeds are intended for general corporate purposes, which is a standard use. This capital infusion is critical for the company's operational runway and strategic initiatives.

check_boxKey Events

• Direct Offering Completed

  Daxor Corp issued 765,958 shares of common stock in a registered direct offering, formalizing the transaction previously announced as finalized on January 26, 2026.

• Pricing and Proceeds

  Shares were sold at $11.75 each, a modest discount to the current market price, generating approximately $8.14 million in net proceeds after placement agent fees and expenses.

• Significant Dilution

  The capital raise is substantial relative to the company's market capitalization, indicating significant dilution for existing shareholders.

• Placement Agent

  Lake Street Capital Markets, LLC acted as the placement agent for the offering.

auto_awesomeAnalysis

This 8-K formalizes the terms and closing of a significant direct offering, following earlier prospectus filings, including the 424B4 on January 26, 2026, which announced the finalization of the offering. The company raised approximately $8.14 million in net proceeds by selling 765,958 shares at $11.75 per share. While the offering price was at a modest discount to the current market price, the capital raise is substantial relative to Daxor's market capitalization, indicating significant dilution for existing shareholders. The proceeds are intended for general corporate purposes, which is a standard use. This capital infusion is critical for the company's operational runway and strategic initiatives.